Genzyme Releases Two New Molecular Tests for Acute Myelogenous Leukemia
Tools Improve Treatment Management of AML Patients
Genzyme Corporation announced the availability of two new molecular tests for acute myelogenous leukemia (AML) with the launch of FLT3 mutation analysis and WT1 RQ-PCR. FLT3 mutations are considered a prognostic indicator of poor survival and response to standard chemotherapies. The WT1 RQ PCR test allows physicians to monitor AML patients for early relapse during and following therapy.
FLT3 receptor mutations are one of the most common genetic abnormalities in AML and have been shown to be an independent predictor of survival. Approximately 30 percent of patients with AML have FLT3 mutations.
Genzyme's exclusive WT1 RQ-PCR test is designed to detect minimal residual disease (MRD), or very low levels of disease. The WT1 gene is expressed in approximately 90 percent of patients with AML. Use of this test enables physicians to identify AML patients at high risk for relapse weeks to months prior to recurrence. The WT1 test is designed to provide oncologists additional information and time to implement other treatment strategies.
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
